• Home
  • Category: Medical Oncology

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

The study assessed the anti-PD-1 monoclonal antibody pembrolizumab in patients with advanced tumors. Objective responses were observed in 30 (29%) of...

Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial

GetUG-AFU 17 was a randomized, open-label, multicentre, phase 3 trial done at 46 French hospitals. 5-year event-free survival was 92% in the adjuvant...

Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial

Adjuvant radiotherapy has been shown to halve the risk of biochemical progression for patients with high-risk disease after radical prostatectomy. Sal...

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Carfilzomib, a next-generation proteasome inhibitor, in combination with lenalidomide and dexamethasone has shown promising efficacy in phase 2 trials...

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

The study investigated COVID-19 risk according to tumor type and patient demographics in patients with cancer in the UK. 319 out of 1044 patients died...

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

CTDNA testing might provide an assessment of the genomic profile of advanced cancer without the need to repeat tumor biopsy. We did an open-label, mul...

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

Addition of atezolizumab to trastuzumab emtansine might potentiate anticancer immunity and enhance the HER2-targeted cytotoxic activity. The KATE2 stu...

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

BRCA1 or BRCA2-mutated breast cancers are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. BROCADE3 was a randomized, double-blind, placebo...

Departments

Recent Posts